Synmosa and EA Pharma announced License Agreement of Patented New Drug for Constipate

Synmosa Biopharma has been successfully in-licensed patented new drugs from Japan to Taiwan. Today, Synmosa announced an Exclusive License Agreement with EA Pharma Co., Ltd to introduce AJG533, a patented new drug for constipation. Synmosa is developing a growing portfolio of digestive system medications including K.B.T Tab.(Mgo), Edema, and PHAZIN(for antiflatulent) etc., to lay out the prescription and self-paid medication market in the digestive system field.